News related to Campath (Alemtuzumab) and/or conditions it is approved for
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia
Source: Health News from Medical News Today [2009.11.19]
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S.
Finding May Give Hope To More Leukemia Patients So They May Live Cancer-Free
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.16]
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. This finding has the potential to change the current medical practice of using one unit of UCB for treatment of patients who are at high risk for recurrence of leukemia and other cancers of the blood and bone marrow. Michael Verneris, M.D.
Leukemia Drug May Help Some Ovarian Cancer Patients (HealthDay)
Source: Y! Health News Search RSS Feed [2009.11.12]
HealthDay - THURSDAY, Nov. 12 (HealthDay News) -- A drug for people with a form of
leukemia holds promise as a possible treatment for ovarian cancer, new
research suggests.
Leukemia Drug May Help Some Ovarian Cancer Patients
Source: MedicineNet Leukemia Specialty [2009.11.12]
Title: Leukemia Drug May Help Some Ovarian Cancer Patients
Category: Health News
Created: 11/12/2009 8:10:00 AM
Last Editorial Review: 11/12/2009
FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer Cells
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.11]
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
Chronic Myelogenous Leukemia (CML)
Source: MedicineNet Anemia Specialty [2009.11.11]
Title: Chronic Myelogenous Leukemia (CML)
Category: Doctor's Views
Created: 11/11/2009 2:29:00 PM
Last Editorial Review: 11/11/2009 2:29:15 PM
Kareem Abdul-Jabbar Has CML Form of Leukemia
Source: MedicineNet Leukemia Specialty [2009.11.11]
Title: Kareem Abdul-Jabbar Has CML Form of Leukemia
Category: Health News
Created: 11/11/2009 9:41:00 AM
Last Editorial Review: 11/11/2009 9:41:07 AM
Advanced Leukemia Successfully Treated With First Use Of Antibody And Stem Cell Transplantation
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.07]
For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.
Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.06]
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML).
Sunesis Completes Enrollment Of Voreloxin REVEAL-1 Trial In Acute Myeloid Leukemia
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.31]
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
Arzerra Approved for Chronic Lymphocytic Leukemia
Source: MedicineNet Diarrhea Specialty [2009.10.28]
Title: Arzerra Approved for Chronic Lymphocytic Leukemia
Category: Health News
Created: 10/27/2009 12:10:00 PM
Last Editorial Review: 10/28/2009
Childhood Acute Lymphoblastic Leukemia
Source: MedicineNet Leukemia Specialty [2009.10.28]
Title: Childhood Acute Lymphoblastic Leukemia
Category: Diseases and Conditions
Created: 10/28/2009 5:07:00 PM
Last Editorial Review: 10/28/2009 5:07:19 PM
Treating Childhood Leukemia With Fewer Side Effects
Source: MedicineNet methotrexate Specialty [2009.09.11]
Title: Treating Childhood Leukemia With Fewer Side Effects
Category: Health News
Created: 9/10/2009 2:10:00 PM
Last Editorial Review: 9/11/2009
Leukemia
Source: MedicineNet Down Syndrome Specialty [2009.06.24]
Title: Leukemia
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 6/24/2009
Leukemia Risk From MS Drug May Be Up
Source: MedicineNet methylprednisolone Specialty [2009.05.01]
Title: Leukemia Risk From MS Drug May Be Up
Category: Health News
Created: 5/1/2009 2:00:00 AM
Last Editorial Review: 5/1/2009
New benchmark study of unrelated bone marrow transplantation for leukemia
Source: The Doctors Lounge - Hematology
Researchers at the University of Minnesota led the largest study to date in patients with leukemia undergoing bone marrow transplantation from unrelated donors.
EntreMed's ENMD-2076 Active In Solid And Hematological Cancers
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.17]
EntreMed, Inc. ( ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer announced the presentation of data for the Phase 1 study for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, in leukemia patients. The Company also announced that it has selected ovarian cancer as an initial Phase 2 indication.
ChemGenex Announces FDA Accepts NDA For Omapro™ (Omacetaxine Mepesuccinate) And Grants The Filing Priority Review Status
Source: Blood / Hematology News From Medical News Today [2009.11.10]
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. The NDA has also been granted Priority Review.
EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application For Review
Source: Blood / Hematology News From Medical News Today [2009.11.10]
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. Health Canada's performance target for the completion of review and a decision is within 300 days.
Targeting PKC-theta Protein: A Way To Inhibit Harmful Immune Responses?
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.10]
For some individuals with leukemia, the best treatment option is to receive a bone marrow transplant from a person who is not an identical genetic match. The donor bone marrow gives rise to immune cells that attack the leukemia (a response known as a graft-versus leukemia [GVL] response). In some cases, however, the immune cells generated by the donor bone marrow attack other cells in the patient's body and this highly toxic response is known as graft-versus-host disease (GVHD).
Stem Cell Therapy International, Inc. And Histostem Korea Announce Providing Hematopoietic Stem Cell To Queen Mary Hospital, Hong Kong
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.11.06]
Stem Cell Therapy International Inc. (OTCBB: SCII) and its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), announced that they recently supplied hematopoietic stem cells to The Queen Mary Hospital of the University of Hong Kong, China, for treatment of Leukemia patients.
Drug Shows Promise In Treating Dangerous Complication Of Erectile Disorder
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2009.11.02]
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Priapism is a condition of persistent painful penile erection in the absence of sexual desire. It is highly associated with sickle cell disease, leukemia and other blood disorders.
Lymphoma Research Foundation Announces Recipients Of CLL/SLL Research Initiative Grants
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2009.10.30]
The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.
|
